Ionis Faces First Real Test Of Tringolza's Broad SHTG Launch As Shares Sit Near Lows

Ionis Pharmaceuticals enters its third-quarter report with a single question hanging over the stock: can the broad Tringolza launch in severe hypertriglyceridemia start to look like the multibillion-dollar franchise management has been promising? The September quarter is the first full period with the SHTG label in hand, after an April price cut deliberately pushed product sales down to a $5 million trough. Meanwhile, the stock has absorbed a failed Phase III, a looming binary readout and a steady slide in confidence. That makes this report less about the headline loss and more about whether the commercial engine can offset rising pipeline risk.

Wall Street expects a non-GAAP loss of $1.00 per share on revenue of about $178.9 million, up 14% from $157.0 million a year ago. That is solid but unspectacular growth. It also marks a sharp step down from the $268.0 million Ionis booked last quarter, which is a reminder that the company's top line still swings with collaboration and milestone timing. The whisper number sits at a loss of $1.11, deeper than consensus. That suggests the more engaged crowd is bracing for heavier spending tied to multiple launches, which effectively lowers the bar on the bottom line. Management has reaffirmed full-year revenue guidance of $875 million to $900 million, a range it raised from $800 million to $825 million earlier in the year. Consensus of roughly $888.7 million sits comfortably in the middle, so a reaffirmation would be expected, while any trim would sting.

The previous call framed Tringolza as the centerpiece. Management lifted its peak-sales view to more than $3 billion, cited prescriptions from day one of the SHTG approval and noted both doses were in the channel within a week. Validation this quarter would mean a visible rebound in Tringolza revenue from the trough, with clear evidence that volume growth is overpowering the lower $40,000 list price. Just as important is payer access. Last quarter, SHTG coverage was flowing largely through medical exceptions, and progress toward formal formulary coverage would signal the launch can scale. Continued record patient starts in FCS would add support. Donzera, which climbed to $26 million last quarter from $16 million, is the other growth line to watch. Another strong sequential gain would confirm that switch-driven demand and repeat prescribers are compounding. On the other side, Wainua's softness in mixed-phenotype ATTR patients is a lingering competitive concern.

The pipeline backdrop has darkened. The CardioTransform miss for eplontersen in ATTR-CM removed a partnered launch that management had once treated as a high-confidence catalyst. Investors will want an update on AstraZeneca's regulatory thinking around the monotherapy subgroup. Zilgenersen and bepirovirsen both had PDUFA dates scheduled before this report, so management's commentary on those launches should help show whether Ionis can carry several new products at once. Above all, the Pelacarsen Horizon readout is due in the second half. Management has already conceded that a miss would pressure its 2028 cash-flow breakeven target, so updated timing and any reiteration of the $425 million to $475 million operating-loss guidance carry real weight.

The market has delivered its own verdict. Shares have dropped about 25% since the last report, trailing the S&P 500 by nearly 27 percentage points. At $41.24 the stock is effectively sitting on its post-earnings low of $41.19 and well below its 200-day moving average near $66.67, a long way from the $86.74 peak of the prior quarter's range. Sentiment has swung from mildly bullish to clearly bearish over the same stretch.

That pessimism cuts both ways. Expectations are now low enough that a convincing Tringolza inflection could reset the conversation. Still, the central issue is whether commercial momentum is strong enough to make the 2028 breakeven goal believable regardless of what Pelacarsen shows. If SHTG revenue and access are clearly building, the growth story holds. If they are not, the stock's slide may look more like a recalibration than an overreaction.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.